Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?

SIMPLE SUMMARY: Sialylation is a post-translational modification that consists in the addition of sialic acid to growing glycan chains on glycoproteins and glycolipids. Aberrant sialylation is an established hallmark of several types of cancer, including breast, ovarian, pancreatic, prostate, colore...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrobono, Silvia, Stecca, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122436/
https://www.ncbi.nlm.nih.gov/pubmed/33921986
http://dx.doi.org/10.3390/cancers13092014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122436/
https://www.ncbi.nlm.nih.gov/pubmed/33921986
http://dx.doi.org/10.3390/cancers13092014

Ejemplares similares